A scathing letter from the Centers for Medicare and Medicaid Services poses a new threat to the blood testing startup following warnings from the FDA. More than ever, Theranos needs to present data showing that its technology works.

from Forbes – Tech http://ift.tt/1NBILdo
via IFTTT